A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo

Table 1 Protective effect of DNA vaccine against H22 tumor cell in vivo (mean ± SD)

Group	n	Tumor latency time (d)	Survival time (d)	Microvessel density	Tumor weight (g)
Vaccine	10	5.20 ± 0.86a	24.47 ± 3.23c	10.10 ± 1.66e	1.41 ± 0.13g
Saline	10	4.00 ± 0.67	14.70 ± 2.63	27.30 ± 3.34	1.79 ± 0.16
Plasmid	10	3.80 ± 0.63	14.30 ± 2.00	25.30 ± 4.64	1.82 ± 0.16

^aP < 0.05,

^cP < 0.05,

^eP < 0.05,

^gP < 0.05 vs plasmid group and saline group.

Table 2 Therapeutic effects of DNA vaccine against H22 tumor cell in vivo (mean ± SD)

Group	n	Survival time (d)	Microvessel density	Tumor weight (g)
Vaccine	10	19.17 ± 1.72a	18.60 ± 3.47c	1.57 ± 0.12e
Saline	10	13.52 ± 1.89	26.90 ± 3.41	1.85 ± 0.09
Plasmid	10	13.67 ± 2.94	25.50 ± 4.43	1.82 ± 0.06

^aP < 0.05,

^cP < 0.05,

^eP < 0.05 vs plasmid group and saline group.

Table 3 Comparison of therapeutic and preventive effects of DNA vaccine (mean ± SD)

Group	n	Survival time (d)	Microvessel density	Tumor weight (g)
Protective vaccine subgroup	10	24.47 ± 3.23a	10.10 ± 1.66c	1.41 ± 0.13e
Therapeutic vaccine subgroup	10	19.17 ± 1.72	18.60 ± 3.47	1.57 ± 0.12

^aP < 0.05,

^cP < 0.05,

^eP < 0.05 vs therapeutic vaccine subgroup.